InMode

Nasdaq: INMD · Yokneam Illit aesthetic medical-device manufacturer; the Israeli category leader in minimally-invasive radiofrequency and laser aesthetic devices

InMode is the Israeli category leader in minimally-invasive aesthetic medical devices — a category that has built durable economics from the converging professional-and-consumer-spending tailwinds of the past decade.

Founded in 2008 in Yokneam Illit by Moshe Mizrahy and Michael Kreindel, InMode productized a category of minimally-invasive radiofrequency and laser-based aesthetic procedures that operate between traditional surgical procedures (face-lifts, liposuction) and non-invasive aesthetic treatments (topical procedures, injectables). The product portfolio is anchored by Morpheus8, the subdermal radiofrequency microneedling platform that has become a category reference in aesthetic medicine. The company listed on Nasdaq in 2019; the post-IPO period has included a substantial 2020-2021 re-rating followed by 2023-2024 compression as the post-pandemic aesthetic-spending cycle inflected.

Origins

InMode was founded in 2008 in Yokneam Illit by Moshe Mizrahy and Michael Kreindel — both senior figures in the Israeli aesthetic medical-device industry, with prior operating experience at Syneron, one of the foundational Israeli aesthetic-device companies. The Yokneam cluster, anchored by the Yokneam Illit industrial park and supported by the deep Israeli electro-optics and laser-engineering talent base, has been the institutional home of Israeli aesthetic medical-device manufacturing for more than two decades.

The minimally-invasive category

The founding commercial insight was that the global aesthetic-medicine category was structurally underserved at the layer between traditional surgical procedures and non-invasive topical or injectable treatments. Aesthetic patients increasingly preferred procedures that produced surgical-quality results without surgical recovery times and surgical costs; aesthetic medical practitioners increasingly wanted technology platforms that could expand their practice-revenue footprint without requiring the operating-room infrastructure that surgical procedures demand. InMode's radiofrequency-and-laser platforms productized the response.

Platform expansion and the Morpheus8 effect

InMode's strategic posture has combined sustained product depth in the minimally-invasive aesthetic category with progressive platform expansion across body areas, treatment types, and practitioner-specialty segments. The Morpheus8 platform, in particular, has expanded substantially beyond its original product positioning to become a category reference in subdermal aesthetic treatments. The commercial model emphasizes direct sales to aesthetic practitioners combined with sustained training and clinical-education investment. The post-2021 strategic emphasis has been on international expansion outside the US-anchored core market and on category extension into adjacent treatment segments.

Israeli aesthetic medical devices at Nasdaq scale

InMode's economic position represents the Israeli public-market exposure to the broader category of aesthetic medical devices — a category that has built durable economics across multiple consumer-spending cycles and that sits at the intersection of Israeli medical-device engineering and global consumer-aesthetic dynamics. The Israeli industrial-medical-device industry is large and globally exported; InMode is the listed flagship at the most consumer-facing end of that industry. Alongside the broader Yokneam medical-device cluster — Lumenis, Alma Lasers, and an extensive long tail of private aesthetic-device manufacturers — InMode anchors the Israeli industrial position in the global aesthetic-medicine category.

Today

Moshe Mizrahy continues as CEO of InMode. The company employs more than seven hundred people, with R&D and manufacturing concentrated in Yokneam Illit and commercial operations distributed across the major aesthetic-medicine markets globally. The post-2023 strategic emphasis has been on the international expansion phase outside the US-anchored core market, on additional Morpheus8 platform extensions, and on navigating the post-pandemic compression in US aesthetic-medicine spending that has weighed on the broader category since 2023.

What's next

The strategic question on InMode for 2026 is the durability of the post-pandemic aesthetic-spending normalization and InMode's relative position inside it. The case for: the underlying category demand is structurally large and globally underserved; the Morpheus8 product position is competitively defensible; international expansion represents substantial untapped revenue. The case against: the US aesthetic-medicine spending cycle has been weak since 2023, the category is contested by both legacy device manufacturers and newer injectables-and-topical entrants, and the company's reliance on direct sales to aesthetic practitioners creates a commercial-cycle dependency that has been particularly visible during the post-pandemic period.

Watch points

• US aesthetic-medicine spending cycle and any signals of category recovery.
• International expansion revenue trajectory outside the US-anchored core market.
• Morpheus8 platform extensions and Morpheus8-derived revenue concentration.
• Competitive dynamics with legacy aesthetic-device manufacturers and the broader injectables-and-topical category.
• Mizrahy continued tenure and any succession-planning signals.

Sources

InMode Ltd., Annual Report on Form 20-F, fiscal year 2024 (filed via SEC EDGAR). InMode investor materials at investors.inmodemd.com.

Olam coverage

See companion Tier A entity profiles of Oddity Tech (Israeli consumer-beauty-and-wellness counterpart on Nasdaq), Kornit Digital (Israeli industrial-technology cohort), and Camtek (Yokneam-and-northern-corridor industrial peer); and the flagship Olam Nasdaq 20.

---

The Olam Editorial Team

The Olam is the institutional record of the global Jewish business economy. Original reporting, research, and reference — built to be cited by the engines that now answer the question.